So, just how attractive are Biosimilars for pharma companies?

By Peter Wallace, Partner in Consulting

Deloitte-uk-biosimilars-for-pharma-companies

Last week’s blog discussed the cost effectiveness of biosimilars and the extent to which they offer value for money for healthcare systems.1 This week’s blog, by Peter Wallace, our lead Partner for digital transformation of Life Sciences and Healthcare, looks at the issue through the lens of the pharma company.

Continue reading

Posted on 20/09/2019 | 0 Comments

The cost-effectiveness of biosimilars: Delivering value for money from pharma spending

By Karen Taylor and Pratik Avhad, Centre for Health Solutions

Deloitte-uk-cost-effectiveness-of-biosimilars

Two months ago, I participated in a Westminster Health Forum panel discussing Biologics and Biosimilars. My remit was to discuss the cost effectiveness of biosimilars and their contribution to value for money in pharma spending. This week’s blog shares the findings from the research we did for the presentation.

Continue reading

Posted on 13/09/2019 | 0 Comments

Delivering the efficiency challenge: The case for system wide efficiency programmes

By Dr Christine Armistead and Gurminder Khaira

Lshc

The combination of significant financial challenges, growing demand for services and major workforce shortages demands a different approach if the NHS is deliver the ambitions set out in the Long Term Plan (LTP). A key priority is the need to put the NHS back onto a sustainable financial footing. This includes major reforms to the NHS’ financial architecture, payment systems and incentives, and a requirement for the NHS to deliver cash-releasing productivity growth of at least 1.1 per cent a year.1

Continue reading

Posted on 06/09/2019 | 0 Comments

The journey of my internship: Titanic or Apollo 11?

By Nahiyan Khan, Intern, Monitor Deloitte

Satellite

My journey as an intern started back in December 2018, alone with my laptop and wavering confidence, fuelled by the daunting stories from my peers about the hundreds of internships they had applied to and the succession of rejections they seemed to get like some sort of corporate ‘tinder’. This, coupled with my third year dissertation constantly on my mind, meant that I didn’t have the most motivated mind set. Still, I remember deciding to apply to one last internship before retiring for the day - Monitor Deloitte. This choice came from a mixture of wanting to get an insight into what strategy consulting actually does, and hearing about Deloitte as a great place for a new graduate to start their career. First would come the immersive online assessment, followed by the job simulation and then, if successful, the final assessment (see Figure 1).

Continue reading

Posted on 30/08/2019 | 0 Comments

Payment reform for integrated care: The risks and rewards of reforming payment mechanisms in the NHS

By Jon White, Deloitte Consulting

ICS

The NHS Five Year Forward View, published in 2014, included proposals to develop five new models of care or ‘Vanguards’ to help transform and integrate health and social care services. Starting in 2015. NHS England allowed health systems the flexibility to introduce new payment mechanisms that would provide better incentives for local care models. Five years on, we have seen pockets of innovation such as the aligned incentive contract in Coastal West Sussex and the outcomes based contract in Greater Manchester. However, by the end of the vanguard phase of the new care models programme, in March 2018, instead of developing new contracts, most vanguards had used a consensus approach based on non-legal agreements between their partners.i

Continue reading

Posted on 23/08/2019 | 0 Comments

Forging a new path to commercialization for cell and gene therapies

By Greg Reh, vice chairman, US and Global Life Sciences leader, Deloitte LLP

Deloitte-uk-green-trees-and-grass

This week’s blog, by Greg Reh from the US firm, first appeared on the US Center for Health Solutions blog site. The blog features Greg’s commentary on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which present unique challenges to pharma companies’ current technology systems.

Continue reading

Posted on 16/08/2019 | 0 Comments

Why improving inclusion and diversity in clinical trials should be a research priority

By Karen Taylor, Director, Centre for Health Solutions

Diversity

Several weeks ago I participated in a panel discussion on inclusion and diversity in clinical trials. My research for the event and the discussion that ensued led me to conclude that while there have been some improvements, the pharma industry continues to struggle to recruit sufficient trial participants from important demographic groups, especially women, racial and ethnic minorities, and the elderly. As a result, the outcomes seen in clinical trials are likely to be unrepresentative of the patient outcomes in the real world.

Continue reading

Posted on 08/08/2019 | 0 Comments

System and place-based decision making

By James Banham and Seb Zanker

ICS

This latest in our series of blogs on the challenges facing Integrated Care Systems (ICS), focuses on how some commissioners are embracing the proposed model of place-based, shared decision making described in the recent guidance from NHS England and NHS Improvement ‘Designing integrated care systems in England1; and what steps they are taking to transition from transactional to more strategic activities.

Continue reading

Posted on 02/08/2019 | 0 Comments

Deal breaker? Mitigating cyber risk in life sciences M&A

By Nadeem Mohammed, Deloitte MCS Limited

Lock

Imagine the scene: it’s Friday night, eight senior executives at one of the world’s largest companies are sitting around a private dining table at a swanky city restaurant. They’re there to celebrate the closure of a transaction they’ve been toiling over for the past 12 months. You’re the Deal Lead, and you’ve just taken a congratulatory phone call from the Chief Executive – the Board are delighted with the acquisition, which will now be at the heart of the company’s growth strategy. You’ve given blood, sweat and tears on this – you raise a glass towards the table and take a quiet moment to reflect on what is surely a career defining moment.

Continue reading

Posted on 26/07/2019 | 0 Comments

Enabling Integrated Care Systems to improve health outcomes through robust population health analytics

By Jon White, Director, Public sector health analytics team

Lshc

This blog is the third in our series of articles examining the challenges in establishing Integrated Care Systems (ICSs) and explores the critical role of population health analytics. Indeed, there is a growing realisation across the healthcare sector about the potential for data analytics to transform everything from strategic planning to clinical decision making. Today, data technology has already transformed many aspects of our lives with unprecedented access to information, connecting people and ideas in ways no-one would have predicted twenty years ago. We have all seen first hand how analytics has impacted other sectors such as retail and marketing and we are now entering a period of rapid innovation in the healthcare sector, with numerous opportunities to utilise data effectively. In this blog we are taking a pragmatic view of some of the things ICSs can do to work collaboratively and focus on improving population health outcomes.

Continue reading

Posted on 19/07/2019 | 0 Comments